SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Aduro Biotech (ADRO)

ADRO RSS Feed
Add ADRO Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 7/26/2016 12:37:29 PM - Followers: 9 - Board type: Free - Posts Today: 0




04/15/2015


ADURO BIOTECH HOME
http://www.aduro.com/ 

About Aduro

Proposed Symbols: ADRO 
CIK: 0001435049 
Address: 626 BANCROFT WAY 
City, State, Zip: BERKELEY ,CA 94710 
Telephone: 510-848-4400 
CEO: Stephen T. Isaacs 
Employee Count: 53 
Fiscal Year:
URL: www.aduro.com 

Company Description 

We are a clinical-stage immuno-oncology company focused on the development of first-in-class technology platforms designed to stimulate robust and durable immune responses against cancer, and our lead product candidate is in a randomized controlled Phase 2b clinical trial in metastatic pancreatic cancer. Immuno-oncology encompasses a class of therapies that leverage the patient’s 
immune system to slow the growth and spread of, or eliminate, tumor cells. We believe a critical distinguishing factor in our approach to immuno-oncology is that our novel therapies initiate powerful innate immune responses and drive targeted, durable adaptive immune responses. The immunotherapy field is rapidly 
advancing with new immuno-oncology combinations that focus on strengthening therapeutic efficacy in a wide range of cancers. We intend to pursue a broad strategy of combining our technology platforms with conventional and novel immuno-oncology therapies, based on their mechanisms of action, safety profiles and versatility. Our pipeline of immuno-oncology product candidates is derived from two proprietary technology platforms: Live, Attenuated, Double-Deleted, or LADD, Listeria monocytogenes and cyclic dinucleotides, or CDNs. Our lead 
LADD product candidate, CRS-207, is currently being developed in metastatic pancreatic cancer and unresectable malignant pleural mesothelioma. In a completed randomized controlled Phase 2a clinical trial in metastatic pancreatic cancer patients, CRS-207 demonstrated a statistically significant improvement in overall survival when combined with GVAX Pancreas, a cellular vaccine product candidate. The 93-patient two-arm Phase 2a clinical trial was designed to compare the combination of CRS-207 and GVAX Pancreas versus GVAX Pancreas alone. The trial met the primary efficacy endpoint of overall survival at an interim analysis and was stopped upon recommendation from the Data Monitoring Committee. Based on the data from this study, our lead immuno-oncology regimen of CRS-207 and GVAX Pancreas was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, or FDA. Breakthrough Therapy designation is intended to expedite the development and review of products that treat serious or life-threatening conditions. We have obtained orphan drug designations from the FDA for CRS-207 and GVAX Pancreas for the treatment of pancreatic cancer and for CRS-207 for the treatment of mesothelioma. Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition. Orphan drug designation entitles a party to certain financial incentives and can provide limited market exclusivity in certain circumstances. We are developing a pipeline of proprietary product candidates, including two product candidates in collaboration with Janssen Biotech, Inc., or Janssen, targeting prostate and lung cancers. In addition, we established a worldwide collaboration with Novartis Pharmaceuticals Corporation, or Novartis, for CDN 
product candidates in oncology. We have intellectual property protection on both of our technology platforms and each of our product candidates, which we believe we will maintain into the 2030s. 
--- 

We were incorporated in California as Oncologic, Inc. in 2000. In 2008, we merged with Triton BioSystems, Inc. and subsequently changed our name to Aduro Biotech, Inc. in 2009. In June 2011, we reincorporated as a Delaware corporation. Our principal executive offices are located at 626 Bancroft Way, 3C, Berkeley, California 94710 and our telephone number is (510) 848-4400. Our website address is www.aduro.com. 

Description of Business 

We are a clinical-stage immuno-oncology company focused on the development of first-in-class technology platforms designed to stimulate robust and durable immune responses against cancer, and our lead product candidate is in a randomized controlled Phase 2b clinical trial in metastatic pancreatic cancer. Immuno-oncology encompasses a class of therapies that leverage the patient’s immune system to slow the growth and spread of, or eliminate, tumor cells. We believe a critical distinguishing factor in our approach to immuno-oncology is that our novel therapies initiate powerful innate immune responses and drive targeted, durable adaptive immune responses. The immunotherapy field is rapidly advancing with new immuno-oncology combinations that focus on strengthening therapeutic efficacy in a wide range of cancers. We intend to pursue a broad strategy of combining our technology platforms with conventional and novel immuno-oncology therapies, based on their mechanisms of action, safety profiles and versatility. Our pipeline of immuno-oncology product candidates is derived from two proprietary technology platforms: Live, Attenuated, Double-Deleted, or LADD, Listeria monocytogenes and cyclic dinucleotides, or CDNs. Our lead LADD product candidate, CRS-207, is currently being developed in metastatic pancreatic cancer and unresectable malignant pleural mesothelioma. In a completed randomized controlled Phase 2a clinical trial in metastatic pancreatic cancer patients, CRS-207 demonstrated a statistically significant improvement in overall survival when combined with GVAX Pancreas, a cellular vaccine product candidate. The 93-patient two-arm Phase 2a clinical trial was designed to compare the combination of CRS-207 and GVAX Pancreas versus GVAX Pancreas alone. The trial met the primary efficacy endpoint of overall survival at an interim analysis and was stopped upon recommendation from the Data Monitoring Committee. Based on the data from this study, our lead immuno-oncology regimen of CRS-207 and GVAX Pancreas was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, or FDA. Breakthrough Therapy designation is intended to expedite the development and review of products that treat serious or life-threatening conditions. We have obtained orphan drug designations from the FDA for CRS-207 and GVAX Pancreas for the treatment of pancreatic cancer and for CRS-207 for the treatment of mesothelioma. Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug or biologic intended to treat a rare disease or condition. Orphan drug designation entitles a party to certain financial incentives and can provide limited market exclusivity in certain circumstances. We are developing a pipeline of proprietary product candidates, including two product candidates in collaboration with Janssen Biotech, Inc., or Janssen, targeting prostate and lung cancers. In addition, we established a worldwide collaboration with Novartis Pharmaceuticals Corporation, or Novartis, for CDN product candidates in oncology. We have intellectual property protection on both of our technology platforms and each of our product candidates, which we believe we will maintain into the 2030s. 

Immuno-oncology is an emerging field of cancer therapy that aims to activate the immune system in the tumor microenvironment to create and enhance anti-tumor immune responses, as well as to overcome the immuno-suppressive mechanisms that cancer cells have developed against the immune system. Recent developments in the field of immuno-oncology, including checkpoint inhibitors—therapies that have mechanisms focused on unmasking hidden cancer cells—have shown the potential to provide dramatic efficacy responses and extended survival, even in cancers where conventional therapies, such as surgery, chemotherapy and radiotherapy, have failed. 

Product candidates from our two immuno-oncology technology platforms are engineered to prime and enhance a patient’s innate and tumor-specific adaptive immune responses to deliver enhanced efficacy over current therapies. Since our product candidates act by stimulating the patient’s own immune system, we believe they have the potential to be safer and more tolerable than existing therapies, such as chemotherapy and radiotherapy. Based on the mechanism of action and safety profile of our technology platforms, we intend to build a deep pipeline of LADD- and CDN-based product candidates that can be readily combinable and synergistic with both conventional and novel therapies, such as checkpoint inhibitors. 

Our vision is to leverage our scientific expertise and the interplay between the innate and adaptive immune responses, to develop safe and effective therapies for the benefit of patients. 
--- 

We were incorporated in California as Oncologic, Inc. in 2000. In 2008, we merged with Triton BioSystems, Inc. and subsequently changed our name to Aduro 
Biotech, Inc. in 2009. In June 2011, we reincorporated as a Delaware corporation. Our principal executive offices are located at 626 Bancroft Way, 3C, Berkeley, California 94710 and our telephone number is (510) 848-4400. Our website address is www.aduro.com. 

Use of Proceeds 

We estimate that the net proceeds from the sale of 7,000,000 shares of common stock in this offering, excluding the proceeds from the concurrent private placement, will be approximately $107.7 million at an assumed initial public offering price of $17.00 per share, after deducting the underwriting discount 
and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional shares in full, we estimate that the net proceeds will be approximately $124.3 million after deducting the underwriting discount and estimated offering expenses payable by us. Our net proceeds from the concurrent private placement will be $25.0 million. 

Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share would increase (decrease) our net proceeds by $6.5 million, assuming the number of shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting the underwriting discount and 
estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. An increase (decrease) of 1,000,000 in the number of shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discount and estimated 
offering expenses payable by us, by approximately $15.8 million, assuming the assumed initial public offering price stays the same. 

We are undertaking this offering in order to access the public capital markets and to increase our liquidity. At December 31, 2014, we had cash and cash equivalents of $119.5 million. We intend to use the net proceeds of this offering and the concurrent private placement, together with our existing cash 
and cash equivalents, as follows: 

. approximately $15.0 million to complete our ongoing ECLIPSE and STELLAR Phase 2b clinical trials in pancreatic cancer; 

. approximately $40.0 million to advance the development of CRS-207 in 
additional indications, including planned Phase 2 clinical trials in mesothelioma and ovarian cancer; 

. approximately $35.0 million to manufacture CRS-207 and GVAX Pancreas at commercial scale in preparation for potential regulatory approval; 

. approximately $30.0 million for other research and development programs involving our LADD and CDN platforms, including ADU-S100; and 

. the remainder for general corporate and working capital purposes. 

However, due to the uncertainties inherent in the product development process, it is difficult to estimate with certainty the exact amounts of the net proceeds from this offering and the concurrent private placement that may be used for the above purposes. The amount and timing of our actual expenditures 
will depend upon numerous factors, including the results of our research and development efforts, the timing and success of our ongoing preclinical studies and clinical trials or preclinical studies and clinical trials we may commence in the future and the timing of regulatoryn submissions. As a result, our management will have broad discretion over the use of the net proceeds from this offering and the concurrent private placement. 

We believe opportunities may exist from time to time to expand our current business through acquisitions or in-licenses of complementary companies, medicines or technologies. While we have no current agreements, commitments or nunderstandings for any specific acquisitions or in-licenses at this time, we may use a portion of the net proceeds for these. 

Pending the use of the proceeds from this offering and the concurrent private nplacement, we intend to invest the net proceeds in interest-bearing, investment-grade securities, certificates of deposit or direct or guaranteed obligations of the U.S. government. 

Competition / Competitors 

The biotechnology and pharmaceutical industries, and the immuno-oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. A wide variety of institutions, including large pharmaceutical companies, specialty biotechnology companies, academic research departments and public and private research institutions, are actively developing potentially competitive products and technologies. We face substantial competition from biotechnology and pharmaceutical companies developing products in immuno-oncology and in our lead indications. They generally fall within the following categories: 

. diversified immuno-oncology: AstraZeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding Ltd and Sanofi SA; immuno-oncology aimed at stimulating immune response: AdaptImmune LLC, Idera Pharmaceuticals, Inc., Immune Design Corp. and NewLink Genetic Corporation; 

. Listeria -based technology: Advaxis, Inc.; 

. pancreatic cancer: Celgene Corporation, Incyte Corporation and Merrimack Pharmaceuticals, Inc.; and mesothelioma: Verastem, Inc. 

While we believe that our product candidates, technology, knowledge and experience provide us with competitive advantages, we face competition from established and emerging pharmaceutical and biotechnology companies, among others. Any product candidates that we successfully develop and commercialize will compete with existing and new therapies that may become available in the future. The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. 

Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated mergers and acquisitions activity in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. 

Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or cheaper than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our product’s entry. We believe the factors determining the success of our programs will be the efficacy, safety and convenience of our product candidates. 

.

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ADRO
Current Price
Volume:
Bid Ask Day's Range
SureTrader
ADRO News: Aduro Biotech Presents Encouraging Preclinical Data Showing Combination Synergy of its Immunotherapy and Checkpoint Inhibitor... 09/27/2016 08:00:00 AM
ADRO News: Aduro Biotech’s Stephen T. Isaacs Named 2016 Visionary Leader by Berkeley Chamber of Commerce 09/26/2016 08:00:00 AM
ADRO News: Aduro Biotech to Present at LEERINK Partners Roundtable Series 09/22/2016 08:00:00 AM
ADRO News: Statement of Changes in Beneficial Ownership (4) 09/21/2016 04:59:15 PM
ADRO News: Statement of Changes in Beneficial Ownership (4) 09/14/2016 04:23:41 PM
PostSubject
#35   This collaboration was announced in dual PRs by north40000 07/26/16 12:37:28 PM
#34   Is it true that there is a $BMY jondoeuk 07/26/16 08:21:30 AM
#33   Dr. Thierry Jahan on the CRS-207 Vaccine in Mesothelioma jondoeuk 07/10/16 09:35:42 AM
#32   Here is an interesting presentation by Dr. Dubensky, jondoeuk 07/10/16 09:34:48 AM
#31   The link doesn't open jondoeuk 07/10/16 08:46:15 AM
#30   Aduro Biotech Presents Encouraging Anti-Tumor Response Data From jondoeuk 07/10/16 08:44:43 AM
#29   Aduro Biotech Inc at the 34th NASDAQ Investor jondoeuk 07/10/16 08:43:56 AM
#28   What Should Aduro BioTech Investors Do Now? venturecapp 05/17/16 12:23:52 PM
#27   $8.85 boom! ClearlyStocks 05/16/16 01:23:53 PM
#26   $8.44 here she goes ClearlyStocks 05/16/16 01:09:38 PM
#25   $8.20s looking good ClearlyStocks 05/16/16 12:42:57 PM
#24   Don't know, but, some good upgrading. BajaWizard 11/28/15 09:51:21 PM
#23   Why is this falling now? akocaman 11/24/15 09:43:46 AM
#22   Why does this one fall more than others? akocaman 06/29/15 01:54:08 PM
#21   Especially at $48. IPO was $17 REMEMBER rtraster 04/16/15 10:44:06 AM
#20   Better alternatives than paying 150% one day later rtraster 04/16/15 10:19:35 AM
#19   Me too...I will wait. north40000 04/15/15 06:14:51 PM
#18   N40k, howdy! Did you get in today? TSmith4659 04/15/15 05:20:36 PM
#17   $ADRO is Crankin'! Up 148% + WOW! ChanceVision 04/15/15 04:07:57 PM
#16   Thank you for reply. you are rite, i iambillionaire 04/15/15 03:28:12 PM
#15   I'm sorry to hear that, Wildbilly 04/15/15 03:23:53 PM
#14   Sorry for posting here, but i need some iambillionaire 04/15/15 02:57:13 PM
#13   ADRO ...$38 at 2:50pm....ridiculous north40000 04/15/15 02:53:57 PM
#12   A double? Blane 04/15/15 12:33:03 PM
#11   Wow what a move! mr_sano 04/15/15 11:27:50 AM
#10   Aduro Biotech (ADRO) IPO Opens Up 88% Wildbilly 04/15/15 11:20:56 AM
#9   ADRO a double @ 11:00 a:m, looks like Wildbilly 04/15/15 11:09:56 AM
#8   EDGAR Pro - ADURO BIOTECH, INC. - IPO Profile Wildbilly 04/14/15 11:15:49 PM
#7   The basic lock up provisions are in the Wildbilly 04/14/15 10:46:32 PM
#6   Lock up expirations? Blane 04/14/15 10:09:17 PM
#5   Hola Blane, probably not on the first day, Wildbilly 04/14/15 09:29:25 PM
#4   Form S-1 Wildbilly 04/14/15 09:17:57 PM
#3   Hey, hey Wildbilly. We just keep running into Blane 04/14/15 01:55:36 PM
#2   Advaxis Shares Rise Ahead Of Rival Aduro's IPO Wildbilly 04/14/15 01:29:47 PM
#1   Aduro Biotech IPO Upsizes Shares And Price To $17 Wildbilly 04/14/15 01:24:26 PM
PostSubject